Avance Clinical at BIO CHINA 2027 | Early-Phase CRO

Why Meet With Avance Clinical at BIO CHINA

A Pathway to Global Development for Chinese Biotechs

Chinese biotechs can begin with rapid early-phase trials in Australia for fast, capital-efficient proof-of-concept, then expand into North America and other key regions through aligned data and regulatory expectations. Integrated program oversight reduces operational complexity at every step.

A Structured Entry Into Asia for North American and European Biotechs

For biotechs based in North America and Europe, Avance Clinical offers a structured entry into Asia for cost-efficient later-phase studies, with access to large, diverse patient populations that support accelerated recruitment. Our expertise spans oncology, metabolic, infectious, hepatic, renal, and CNS indications.

Faster, Smarter Early Trials with the Australian Advantage

Australia lets biotechs start most early-phase trials without an IND, with study start-up in 5–6 weeks from final protocol to approval and R&D rebates of up to 43.5% on eligible spend. Experienced investigators and world-class sites support the work, and the data is accepted by the TGA, FDA, EMA, and MHRA.

One Partner Across Every Region with GlobalReady

Through the GlobalReady program, biotechs work with a single CRO from first-in-human through later-phase, multi-country studies across Australia, Asia Pacific, China, North America, and Europe. This integrated approach is designed to maintain aligned teams and consistent data standards, so programs don’t rebuild relationships or processes at every border.